Figshare
open access
CC BY-NC 4.0
<sup>177</sup>Lu-Labeled Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 Monoclonal Antibody-Targeted Therapy for Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma (ccRCC) remains a therapeutic challenge. Ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) is highly expressed in ccRCC tissues and cell lines, representing a promising target. This study aimed to conjugate lutetium-177 (177Lu) to an anti-human ENP
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer#864655
- Pharmaceutical Management in Targeted Radioligand Therapy#837227
- Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases#1362350
- RBN-2397 in Combination With Pembrolizumab in Patients With SCCL#1194876
- Small molecules targeting regulated cell death for chronic kidney disease therapy.#67499
Record · ID 1203280
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive